Loading…
SULFAMETHOXAZOLE AND TRIMETHOPRIM FOR is a brand name for Sulfamethoxazole, supplied as a solution. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Sulfamethoxazole and Trimethoprim for Injection, USP (sulfamethoxazole and trimethoprim) is indicated for treatment of infections associated with the following gram-positive and gram- negative organisms: Gram-Negative Organisms Haemophilus influenzae Neisseria gonorrhoeae Escherichia coli Klebsiella species…
Verbatim from this product's HC label. Tap a section to expand.
). 2 CONTRAINDICATIONS Sulfamethoxazole and Trimethoprim for Injection, USP: • is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
For a complete listing (see
). Appropriate dosage adjustments should be made (see 4 DOSAGE AND ADMINISTRATION). 2 CONTRAINDICATIONS Sulfamethoxazole and Trimethoprim for Injection, USP: • is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
For a complete listing (see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING). • is contraindicated in patients with a history of drug-induced immune thrombocytopenia, with use of trimethoprim and/or sulfonamides, and in patients with documented megaloblastic anemia due to folate deficiency, evidence of marked parenchymal damage, or blood dyscrasias.
• is contraindicated in patients with marked renal impairment where repeated measurements monitoring plasma drug concentrations cannot be performed (see 7 WARNINGS AND PRECAUTIONS). • is contraindicated in pregnant patients and in nursing mothers, because sulfonamides pass the placenta and are excreted in the milk and may cause kernicterus.
• is contraindicated in premature babies and full-term infants less than two months of age. • should not be given to patients with acute porphyria. • must not be given in combination with dofetilide (see
, General 11/2024 7 WARNINGS AND PRECAUTIONS, Immune 11/2024 7 WARNINGS AND PRECAUTIONS, Respiratory 11/2024 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES .....................................................................................
2 TABLE OF CONTENTS ........................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION ............................................................... 4 1 INDICATIONS .................................................................................................................
1 Pediatrics ................................................................................................................... 2 Geriatrics ...................................................................................................................
5 2 CONTRAINDICATIONS .................................................................................................... 6 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................... 6 4 DOSAGE AND ADMINISTRATION ....................................................................................
1 Dosing Considerations ............................................................................................... 2 Recommended Dose and Dosage Adjustment .......................................................... 3 Reconstitution ...........................................................................................................
4 Administration ......................................................................................................... 10 5 OVERDOSAGE..............................................................................................................
10 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ................................. 11 7 WARNINGS AND PRECAUTIONS .................................................................................. 1 Special Populations .................................................................................................
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Sulfamethoxazole in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
1 Pregnant Women .......................................................................................... 2 Breast-feeding ............................................................................................... 3 Pediatrics .......................................................................................................
4 Geriatrics ....................................................................................................... 20 8 ADVERSE REACTIONS ..................................................................................................
1 Adverse Reaction Overview ..................................................................................... 3 Less Common Clinical Trial Adverse Reactions ........................................................ 21 9 DRUG INTERACTIONS ..................................................................................................
3 Drug-Behavioural Interactions................................................................................. 4 Drug-Drug Interactions ............................................................................................ 5 Drug-Food Interactions............................................................................................
6 Drug-Herb Interactions ............................................................................................ 7 Drug-Laboratory Test Interactions........................................................................... 26 10 CLINICAL PHARMACOLOGY .......................................................................................
1 Mechanism of Action............................................................................................. 3 Pharmacokinetics ..................................................................................................
27 11 STORAGE, STABILITY AND DISPOSAL ......................................................................... 29 PART II: SCIENTIFIC INFORMATION ................................................................................ 30 13 PHARMACEUTICAL INFORMATION ............................................................................
30 15 MICROBIOLOGY ........................................................................................................ 30 16 NON-CLINICAL TOXICOLOGY......................................................................................
37 17 SUPPORTING PRODUCT MONOGRAPHS .................................................................... 41 PATIENT MEDICATION INFORMATION............................................................................ 42 Sulfamethoxazole and Trimethoprim for Injection, USP Product Monograph Page 4 of 54 Unclassified / Non classifié PART I: HEALTH PROFESSIONAL INFORMATION 1 INDICATIONS Sulfamethoxazole and Trimethoprim for Injection, USP (sulfamethoxazole and trimethoprim) is indicated for treatment of infections associated with the following gram-positive and gram- negative organisms: Gram-Negative Organisms Haemophilus influenzae Neisseria gonorrhoeae Escherichia coli Klebsiella species Enterobacter (Aerobacter) aerogenes Proteus mirabilis Proteus vulgaris Salmonella species Shigella species Vibrio cholerae Gram-Positive Organisms Streptococcus pyogenes Streptococcus viridans Staphylococcus albus Staphylococcus aureus Diplococcus pneumoniae Other Organisms Brucella melitensis Nocardia asteroides Nocardia brasiliensis Paracoccidioides brasiliensis Pneumocystis jiroveci Streptomyces somaliensis Sensitivity tests should be performed wherever possible to determine choice of therapy.
These tests should be repeated if there is a […]